Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for dust mite asthma sufferers?

NCT ID NCT05720325

First seen Mar 17, 2026 · Last updated May 19, 2026 · Updated 8 times

Summary

This study looks at whether dupilumab, an approved asthma drug, can reduce allergic reactions in adults with house dust mite asthma. Participants will be exposed to dust mites in a special chamber to measure changes in their nasal and blood gene activity. The trial involves 88 adults aged 18 to 65 and aims to understand how the drug works at a molecular level.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA, ALLERGIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Biogenics Research Chamber

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Texas Health Science Center at San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

Conditions

Explore the condition pages connected to this study.